研究疾病:
|
代谢相关脂肪性肝病(MAFLD)
|
研究疾病代码:
|
|
Target disease:
|
Metabolically associated fatty liver disease
|
Target disease code:
|
研究类型:
Study type:
|
干预性研究
Interventional study
|
研究设计:
Study design:
|
随机平行对照
randomized controlled trial(parallel group design)
|
研究所处阶段:
Study phase:
|
探索性研究/预试验
Pilot clinical trial
|
研究目的:
|
代谢相关脂肪性肝病全球患病率达25%且无FDA批准的有效药物。苓荷颗粒治疗有效但缺少临床证据。拟以MRI肝脂肪定量为主要疗效指标,通过随机对照试验评价其治疗肥胖型代谢相关脂肪性肝病疗效,并找出有效人群适应症以建立预测模型,为提高疗效、个体化治疗及形成可推广的代谢相关脂肪性肝病诊疗技术及新药研发提供证据。
|
Objectives of Study:
|
The global prevalence of metabolic-related fatty liver disease has reached 25 % with no effective drugs approved by FDA. Ling-He Granule is effective but lack clinical evidence. The MRI quantification of liver fat, which is prepared to be the main efficacy indicators, is used to evaluate therapeutic effect of obese metabolic-related fatty liver disease by randomized controlled trial, in order to find out adaptation diseases of applicable population to build a prediction model, which can provide evidence for improving curative efficacy, individualizing treatment, and forming a generalizable diagnosis and treatment technology for MAFLD and new drug development.
|
药物成份或治疗方案详述:
|
苓荷颗粒:茯苓15克、净山楂8克、荷叶8克、佛手10克、决明子10克、丹参10克、陈皮8克、玉米须 15克。
|
Description for medicine or protocol of treatment in detail:
|
Ling-He Granules: Tuckahoe 15g, Hawthorn 8g, Lotus leaf 8g,Finger citron fruit 10g, Sickle senna seed 10g, Salvia miltiorrhiza 10g, Chenpi 8g, Corn silk 15g.
|
纳入标准:
|
参照“2020年代谢相关脂肪性肝病新定义的国际专家共识”MAFLD的诊断标准、“2017年非酒精性脂肪性肝病中西医结合诊疗共识意见中医证候标准”(非酒精性脂肪性肝病中西医结合诊疗共识意见(2017年)制定的中医痰、湿、瘀证候诊断标准:①年龄18-60周岁;②符合MAFLD(肥胖型)诊断标准并同时符合中医痰、湿、瘀证候诊断标准;③24≤BMI<30kg/m2;④MRI PDFF均值>8%,愿意接受定期相关的常规理化检查;⑤签署知情同意书。
|
Inclusion criteria
|
Referring to diagnostic criteria for MAFLD based on the new definition of metabolic fatty liver disease in 2020, the diagnostic criteria of Phlegm, Dampness and Blood Stasis Syndrome established by the consensus opinion on the diagnosis and treatment of non-alcoholic fatty liver disease by integrated traditional Chinese and western medicine (2017) are as follows::①Age 18-60 years; ②Compliance with MAFLD (obesity type) diagnostic criteria and TCM phlegm, dampness, blood stasis syndrome diagnostic criteria; ③24≤BMI<30kg/m2; ④MRI PDFF > 8 %, willing to accept regular physical and chemical examinations; ⑤Sign informed consent.
|
排除标准:
|
①丙氨酸氨基转移酶/天冬氨酸氨基转移酶>5×ULN(标准上限)、总胆红素 > 2 × ULN;②酒精性脂肪性肝病;③合并病毒性、自身免疫性及其他肝病,或服用可能导致脂肪肝的药物者;④合并糖尿病、恶性肿瘤、结缔组织疾病及严重心、肝、造血、神经系统并发症,或明确有其他重要疾病者;⑤中医辨证属肝肾阴虚、脾肾阳虚等典型虚证者;⑥妊娠或哺乳期妇女、过敏体质、对药物过敏及有精神类疾患者;⑦近一年内实施过胃肠减肥手术或近3个月内服减肥药体重下降>10%者;⑧近3个月来服用其他治疗用药而影响疗效评价,或者近一个月内参加其他临床试验者。
|
Exclusion criteria:
|
①Alanine aminotransferase / aspartate aminotransferase > 5 × ULN ( standard upper limit ), total bilirubin > 2 × ULN; ②Alcoholic fatty liver disease; ③Combined with viral, autoimmune and other liver diseases, or taking drugs that may cause fatty liver; ④Combined with diabetes, malignant tumors, connective tissue diseases and severe heart, liver, hematopoietic, and nervous system complications , Or clearly have other important diseases; ⑤TCM Syndrome Differentiation of Liver and Kidney Yin Deficiency, Spleen and Kidney Yang Deficiency and Other Typical Deficiency Syndrome; ⑥Pregnant or breastfeeding women, allergic physique, allergic to drugs, and patients with mental illness; ⑦Patients who have undergone gastrointestinal bariatric surgery within the past year or who have taken weight-loss drugs within the past three months have lost >10%; ⑧Patients who took other therapeutic drugs in the past three months affected efficacy evaluation or participated in other clinical trials in the past month.
|
研究实施时间:
Study execute time:
|
从From
2022-05-19
至To
2024-08-01
|
征募观察对象时间:
Recruiting time:
|
从From
2022-05-19
至To
2023-04-30
|